Aptose Total Stockholder Equity vs Short Term Investments Analysis

APTO Stock

USD 1.18 0.05 4.07%

Aptose Biosciences financial indicator trend analysis is way more than just evaluating Aptose Biosciences prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Aptose Biosciences is a good investment. Please check the relationship between Aptose Biosciences Total Stockholder Equity and its Short Term Investments accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aptose Biosciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

To learn how to invest in Aptose Stock, please use our How to Invest in Aptose Biosciences guide.

Total Stockholder Equity vs Short Term Investments

Total Stockholder Equity vs Short Term Investments Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Aptose Biosciences Total Stockholder Equity account and Short Term Investments. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Aptose Biosciences' Total Stockholder Equity and Short Term Investments is 0.56. Overlapping area represents the amount of variation of Total Stockholder Equity that can explain the historical movement of Short Term Investments in the same time period over historical financial statements of Aptose Biosciences, assuming nothing else is changed. The correlation between historical values of Aptose Biosciences' Total Stockholder Equity and Short Term Investments is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Stockholder Equity of Aptose Biosciences are associated (or correlated) with its Short Term Investments. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Short Term Investments has no effect on the direction of Total Stockholder Equity i.e., Aptose Biosciences' Total Stockholder Equity and Short Term Investments go up and down completely randomly.

Correlation Coefficient

0.56

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Short Term Investments

Short Term Investments is an item under the current assets section of Aptose Biosciences balance sheet. It contains any investments Aptose Biosciences undertook that will expire in less than one year. These accounts contain financial instruments such as stocks or bonds that Aptose Biosciences can easily liquidate in the marketplace.

Most indicators from Aptose Biosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Aptose Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aptose Biosciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

To learn how to invest in Aptose Stock, please use our How to Invest in Aptose Biosciences guide.At this time, Aptose Biosciences' Selling General Administrative is very stable compared to the past year. As of the 16th of May 2024, Sales General And Administrative To Revenue is likely to grow to 47.11, while Issuance Of Capital Stock is likely to drop about 5.8 M.

	2021	2022	2023	2024 (projected)
Net Interest Income	94K	788K	1.4M	1.5M
Interest Income	94K	788K	1.4M	1.5M

Net Interest Income Interest Income

Aptose Biosciences fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Non Currrent Assets Other	Intangible Assets	Net Tangible Assets	Common Stock Total Equity	Short Term Debt	Common Stock
Total Assets		0.09	0.25	0.99	0.74	-0.97	-0.39	0.34	0.96	0.55	0.64	1.0	-0.2	0.56	0.11	-0.3	0.37	0.28	0.08	1.0	-0.02	-0.19	0.93	0.47	0.02	0.72
Other Current Liab	0.09		0.95	-0.04	0.44	-0.06	-0.85	0.69	0.1	0.67	-0.12	0.06	-0.14	-0.01	0.08	0.87	0.88	0.94	0.91	0.08	0.86	-0.22	0.37	0.81	-0.04	0.53
Total Current Liabilities	0.25	0.95		0.12	0.63	-0.22	-0.93	0.87	0.25	0.78	-0.03	0.23	-0.15	0.09	0.23	0.72	0.96	1.0	0.81	0.24	0.91	-0.27	0.47	0.88	-0.04	0.69
Total Stockholder Equity	0.99	-0.04	0.12		0.67	-0.96	-0.27	0.23	0.96	0.46	0.66	0.99	-0.18	0.56	0.08	-0.4	0.25	0.15	-0.02	0.99	-0.14	-0.16	0.89	0.37	0.02	0.64
Property Plant And Equipment Net	0.74	0.44	0.63	0.67		-0.71	-0.63	0.74	0.72	0.85	0.49	0.73	-0.24	0.33	0.32	0.08	0.64	0.65	0.43	0.74	0.46	-0.09	0.75	0.7	-0.04	0.81
Net Debt	-0.97	-0.06	-0.22	-0.96	-0.71		0.34	-0.32	-1.0	-0.54	-0.73	-0.97	0.17	-0.34	-0.16	0.28	-0.3	-0.24	-0.11	-0.97	0.07	0.2	-0.91	-0.45	-0.06	-0.66
Retained Earnings	-0.39	-0.85	-0.93	-0.27	-0.63	0.34		-0.83	-0.37	-0.72	-0.11	-0.36	0.14	-0.21	-0.25	-0.55	-0.93	-0.93	-0.66	-0.38	-0.81	0.55	-0.57	-0.94	-0.13	-0.84
Accounts Payable	0.34	0.69	0.87	0.23	0.74	-0.32	-0.83		0.34	0.78	0.08	0.32	-0.1	0.12	0.41	0.39	0.86	0.88	0.51	0.33	0.86	-0.25	0.44	0.77	-0.1	0.72
Cash	0.96	0.1	0.25	0.96	0.72	-1.0	-0.37	0.34		0.57	0.73	0.96	-0.18	0.33	0.17	-0.24	0.33	0.28	0.15	0.96	-0.04	-0.21	0.92	0.47	0.07	0.66
Non Current Assets Total	0.55	0.67	0.78	0.46	0.85	-0.54	-0.72	0.78	0.57		0.34	0.53	-0.27	0.16	0.24	0.38	0.75	0.8	0.66	0.55	0.62	-0.14	0.66	0.79	0.04	0.65
Other Assets	0.64	-0.12	-0.03	0.66	0.49	-0.73	-0.11	0.08	0.73	0.34		0.65	-0.13	0.03	0.49	-0.31	0.03	0.0	0.08	0.64	-0.31	-0.15	0.59	0.25	0.2	0.37
Cash And Short Term Investments	1.0	0.06	0.23	0.99	0.73	-0.97	-0.36	0.32	0.96	0.53	0.65		-0.19	0.56	0.1	-0.32	0.34	0.25	0.06	1.0	-0.05	-0.18	0.92	0.45	0.02	0.7
Common Stock Shares Outstanding	-0.2	-0.14	-0.15	-0.18	-0.24	0.17	0.14	-0.1	-0.18	-0.27	-0.13	-0.19		0.09	0.09	-0.07	-0.15	-0.16	-0.15	-0.2	-0.14	-0.07	-0.04	-0.09	0.05	-0.18
Short Term Investments	0.56	-0.01	0.09	0.56	0.33	-0.34	-0.21	0.12	0.33	0.16	0.03	0.56	0.09		-0.12	-0.33	0.25	0.1	-0.17	0.56	0.01	-0.05	0.49	0.2	-0.15	0.43
Non Current Liabilities Total	0.11	0.08	0.23	0.08	0.32	-0.16	-0.25	0.41	0.17	0.24	0.49	0.1	0.09	-0.12		-0.04	0.16	0.24	0.12	0.11	0.12	-0.3	0.14	0.24	0.22	0.24
Other Current Assets	-0.3	0.87	0.72	-0.4	0.08	0.28	-0.55	0.39	-0.24	0.38	-0.31	-0.32	-0.07	-0.33	-0.04		0.56	0.7	0.89	-0.31	0.71	-0.13	0.01	0.49	-0.13	0.12
Other Stockholder Equity	0.37	0.88	0.96	0.25	0.64	-0.3	-0.93	0.86	0.33	0.75	0.03	0.34	-0.15	0.25	0.16	0.56		0.96	0.69	0.36	0.84	-0.22	0.54	0.88	-0.03	0.77
Total Liab	0.28	0.94	1.0	0.15	0.65	-0.24	-0.93	0.88	0.28	0.8	0.0	0.25	-0.16	0.1	0.24	0.7	0.96		0.81	0.27	0.91	-0.27	0.49	0.88	-0.05	0.7
Property Plant And Equipment Gross	0.08	0.91	0.81	-0.02	0.43	-0.11	-0.66	0.51	0.15	0.66	0.08	0.06	-0.15	-0.17	0.12	0.89	0.69	0.81		0.08	0.65	-0.11	0.38	0.67	-0.07	0.37
Total Current Assets	1.0	0.08	0.24	0.99	0.74	-0.97	-0.38	0.33	0.96	0.55	0.64	1.0	-0.2	0.56	0.11	-0.31	0.36	0.27	0.08		-0.03	-0.19	0.93	0.47	0.01	0.72
Non Currrent Assets Other	-0.02	0.86	0.91	-0.14	0.46	0.07	-0.81	0.86	-0.04	0.62	-0.31	-0.05	-0.14	0.01	0.12	0.71	0.84	0.91	0.65	-0.03		-0.21	0.16	0.72	-0.15	0.51
Intangible Assets	-0.19	-0.22	-0.27	-0.16	-0.09	0.2	0.55	-0.25	-0.21	-0.14	-0.15	-0.18	-0.07	-0.05	-0.3	-0.13	-0.22	-0.27	-0.11	-0.19	-0.21		-0.29	-0.47	-0.48	-0.45
Net Tangible Assets	0.93	0.37	0.47	0.89	0.75	-0.91	-0.57	0.44	0.92	0.66	0.59	0.92	-0.04	0.49	0.14	0.01	0.54	0.49	0.38	0.93	0.16	-0.29		0.66	0.03	0.77
Common Stock Total Equity	0.47	0.81	0.88	0.37	0.7	-0.45	-0.94	0.77	0.47	0.79	0.25	0.45	-0.09	0.2	0.24	0.49	0.88	0.88	0.67	0.47	0.72	-0.47	0.66		0.24	0.82
Short Term Debt	0.02	-0.04	-0.04	0.02	-0.04	-0.06	-0.13	-0.1	0.07	0.04	0.2	0.02	0.05	-0.15	0.22	-0.13	-0.03	-0.05	-0.07	0.01	-0.15	-0.48	0.03	0.24		0.12
Common Stock	0.72	0.53	0.69	0.64	0.81	-0.66	-0.84	0.72	0.66	0.65	0.37	0.7	-0.18	0.43	0.24	0.12	0.77	0.7	0.37	0.72	0.51	-0.45	0.77	0.82	0.12

Click cells to compare fundamentals

Aptose Biosciences Account Relationship Matchups

Aptose Biosciences fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	100.5M	126.3M	82.5M	51.0M	12.9M	12.3M
Other Current Liab	3.1M	4.1M	6.0M	5.7M	13.9M	14.6M
Total Current Liabilities	5.5M	6.8M	8.2M	12.3M	15.2M	16.0M
Total Stockholder Equity	93.9M	118.9M	74.2M	37.7M	(2.9M)	(2.7M)
Property Plant And Equipment Net	1.7M	1.2M	788K	1.5M	1.1M	574.3K
Net Debt	(78.3M)	(116.3M)	(38.5M)	(35.7M)	(8.2M)	(8.6M)
Retained Earnings	(301.9M)	(357.2M)	(422.5M)	(464.3M)	(512.9M)	(487.3M)
Accounts Payable	2.0M	2.2M	1.7M	6.3M	3.5M	3.7M
Cash	79.8M	117.4M	39.1M	37.0M	9.2M	15.8M
Non Current Assets Total	1.7M	1.2M	788K	1.5M	1.1M	1.7M
Cash And Short Term Investments	97.6M	122.4M	79.1M	47.0M	9.2M	8.7M
Common Stock Shares Outstanding	3.3M	5.5M	5.9M	6.2M	6.8M	6.4M
Short Term Investments	798K	440K	17.8M	5M	40.0M	10.0M
Liabilities And Stockholders Equity	100.5M	126.3M	82.5M	51.0M	12.9M	12.3M
Non Current Liabilities Total	1.0M	535K	115K	1.0M	617.8K	586.9K
Other Current Assets	141K	129K	133K	257K	2.6M	2.8M
Other Stockholder Equity	34.6M	50.9M	63.7M	68.9M	71.8M	75.4M
Total Liab	6.6M	7.3M	8.3M	13.3M	15.8M	16.6M
Property Plant And Equipment Gross	1.7M	1.2M	323K	211K	3.9M	4.1M
Total Current Assets	98.8M	125.1M	81.7M	49.5M	11.8M	11.2M
Non Currrent Assets Other	(94.0)	(48.0)	465K	1.3M	1.2M	1.2M
Intangible Assets	1.0	142.0	94.0	48.0	43.2	41.04
Net Tangible Assets	93.8M	118.9M	74.2M	37.7M	43.4M	45.6M
Common Stock Total Equity	365.5M	429.5M	437.4M	437.5M	503.1M	528.3M
Retained Earnings Total Equity	(301.9M)	(357.2M)	(422.5M)	(464.3M)	(417.9M)	(397.0M)
Common Stock	365.5M	429.5M	437.4M	437.5M	442.5M	231.4M
Property Plant Equipment	1.6M	1.1M	788K	211K	189.9K	364.1K
Capital Surpluse	34.6M	50.9M	63.7M	68.9M	79.2M	51.4M
Net Invested Capital	93.9M	118.9M	74.2M	37.7M	(2.9M)	(2.8M)
Net Working Capital	93.2M	118.3M	73.6M	37.2M	(3.4M)	(3.2M)
Capital Stock	365.5M	429.5M	437.4M	437.5M	444.8M	435.6M

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Aptose Biosciences in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Aptose Biosciences' short interest history, or implied volatility extrapolated from Aptose Biosciences options trading.

Pair Trading with Aptose Biosciences

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aptose Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aptose Biosciences will appreciate offsetting losses from the drop in the long position's value.

Moving together with Aptose Stock

0.89

VRDN

Viridian Therapeutics

Pair Corr

Moving against Aptose Stock

0.78	ACB	Aurora Cannabis Financial Report 12th of June 2024	Pair Corr
0.75	CGC	Canopy Growth Corp Financial Report 27th of June 2024	Pair Corr

The ability to find closely correlated positions to Aptose Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aptose Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aptose Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aptose Biosciences to buy it.

The correlation of Aptose Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aptose Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aptose Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Aptose Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Aptose Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Aptose Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aptose Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aptose Biosciences Stock:

How To Invest In Aptose

Details

Is Aptose Stock a good investment?

Details

What is Aptose Biosciences' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aptose Biosciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

To learn how to invest in Aptose Stock, please use our How to Invest in Aptose Biosciences guide.

You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.

Complementary Tools for Aptose Stock analysis

When running Aptose Biosciences' price analysis, check to measure Aptose Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aptose Biosciences is operating at the current time. Most of Aptose Biosciences' value examination focuses on studying past and present price action to predict the probability of Aptose Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aptose Biosciences' price. Additionally, you may evaluate how the addition of Aptose Biosciences to your portfolios can decrease your overall portfolio volatility.

	Transaction History View history of all your transactions and understand their impact on performance
	Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
	Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
	USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA
	Insider Screener Find insiders across different sectors to evaluate their impact on performance

Is Aptose Biosciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aptose Biosciences. If investors know Aptose will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aptose Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(7.58)

Return On Assets

(1.02)

Return On Equity

(2.94)

The market value of Aptose Biosciences is measured differently than its book value, which is the value of Aptose that is recorded on the company's balance sheet. Investors also form their own opinion of Aptose Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Aptose Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aptose Biosciences' market value can be influenced by many factors that don't directly affect Aptose Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Aptose Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aptose Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aptose Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Aptose Total Stockholder Equity vs Short Term Investments Analysis

Total Stockholder Equity vs Short Term Investments

Total Stockholder Equity vs Short Term Investments Correlation Analysis

Correlation Coefficient

Total Stockholder Equity

Short Term Investments

Aptose Biosciences fundamental ratios Correlations

Aptose Biosciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Aptose Biosciences fundamental ratios Accounts

Pair Trading with Aptose Biosciences

Moving together with Aptose Stock

Moving against Aptose Stock

Complementary Tools for Aptose Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Liab	+ 1.0	Total Current Liabilities
Total Current Assets	+ 1.0	Cash And Short Term Investments
Total Stockholder Equity	+ 0.99	Total Assets
Cash And Short Term Investments	+ 0.99	Total Stockholder Equity

Cash	- 1.0	Net Debt
Total Current Assets	- 0.97	Net Debt
Cash And Short Term Investments	- 0.97	Net Debt
Net Debt	- 0.97	Total Assets
Net Debt	- 0.96	Total Stockholder Equity
Common Stock Total Equity	- 0.94	Retained Earnings